BioWorld

Jan. 13, 2014

Money Raised By Biotech In 2014 vs. 2013

Venture capital holds steady but additional sources needed

It is that time of year again when the biotech lens sets its focus squarely on San Francisco with more than 12,000 business executives, investors and analysts heading to town for the J.P. Morgan Healthcare, Biotech Showcase and OneMedForum events. The common denominator for all these meetings is money. Read More

Reverse splits couldn’t hold these companies down

Reverse splits have a bad reputation amongst investors, causing biotechs, for the most part, to avoid them at all cost. Read More

Week in Review

Money Raised By Biotech Jan. 1 - 9, 2014

Word on the Street

Week in Washington

Phase I clinical trials update: December 2013

Phase II clinical trials update: December 2013

Phase III clinical trials update: December 2013

American Society of Hematology: December 2013

Pharma clinical and FDA action update: December 2013

Non-U.S. clinical trials and regulatory actions: December 2013

FDA submissions, approvals & other actions: December 2013

The Week's Biggest Gainers And Losers

BioWorld Stock Report For Public Biotechnology Companies

Today's news in brief

BioWorld

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

TL1A is overexpressed in hidradenitis suppurativa

BioWorld Science

Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...